Dual target strategy

Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease

Marie Therese Fuzzati-Armentero, Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gianfilippo Antoninetti, Fabio Blandini, Younis Baqi, Christa E. Müller, Rosaria Volpini, Giulia Costa, Nicola Simola, Annalisa Pinna

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2AR) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2AR antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94). Chronic treatment with MPEP or MSX-3 alone, but not with ANR 94, reduced the toxin-induced loss of dopaminergic neurons in the substantia nigra pars compacta. Combining MSX-3 and MPEP further improved the neuroprotective effect of either antagonists. At the behavioral level, ANR 94 and MSX-3 given alone significantly potentiated l-DOPA-induced turning behavior. Combination of either A2AR antagonists with MPEP synergistically increased L-DOPA-induced turning. This effect was dose-dependent and required subthreshold drug concentration, which per se had no motor stimulating effect. Our findings suggest that co-treatment with A2AR and mGluR5 antagonists provides better therapeutic benefits than those produced by either drug alone. Our study sheds some light on the efficacy and advantages of combined non-dopaminergic PD treatment using low drug concentration and establishes the basis for in-depth studies to identify optimal doses at which these drugs reach highest efficacy.

Original languageEnglish
Pages (from-to)740-747
Number of pages8
JournalJournal of Neurochemistry
Volume134
Issue number4
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Parkinson Disease
Rodentia
Pharmaceutical Preparations
Metabotropic Glutamate 5 Receptor
Adenosine A2A Receptors
Oxidopamine
Dopaminergic Neurons
Neuroprotective Agents
Neurons
Disease Progression
Rats
8-ethoxy- 9-ethyladenine
Therapeutics
pyridine

Keywords

  • 6-OHDA
  • adenosine A<inf>2A</inf> receptor
  • antagonist
  • metabotropic glutamate receptor
  • neurodegeneration
  • neuroprotection

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Dual target strategy : Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease. / Fuzzati-Armentero, Marie Therese; Cerri, Silvia; Levandis, Giovanna; Ambrosi, Giulia; Montepeloso, Elena; Antoninetti, Gianfilippo; Blandini, Fabio; Baqi, Younis; Müller, Christa E.; Volpini, Rosaria; Costa, Giulia; Simola, Nicola; Pinna, Annalisa.

In: Journal of Neurochemistry, Vol. 134, No. 4, 01.08.2015, p. 740-747.

Research output: Contribution to journalArticle

Fuzzati-Armentero, MT, Cerri, S, Levandis, G, Ambrosi, G, Montepeloso, E, Antoninetti, G, Blandini, F, Baqi, Y, Müller, CE, Volpini, R, Costa, G, Simola, N & Pinna, A 2015, 'Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease', Journal of Neurochemistry, vol. 134, no. 4, pp. 740-747. https://doi.org/10.1111/jnc.13162
Fuzzati-Armentero, Marie Therese ; Cerri, Silvia ; Levandis, Giovanna ; Ambrosi, Giulia ; Montepeloso, Elena ; Antoninetti, Gianfilippo ; Blandini, Fabio ; Baqi, Younis ; Müller, Christa E. ; Volpini, Rosaria ; Costa, Giulia ; Simola, Nicola ; Pinna, Annalisa. / Dual target strategy : Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease. In: Journal of Neurochemistry. 2015 ; Vol. 134, No. 4. pp. 740-747.
@article{a2658b4125c54aa4aece1ed0832a2c45,
title = "Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease",
abstract = "The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2AR) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2AR antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94). Chronic treatment with MPEP or MSX-3 alone, but not with ANR 94, reduced the toxin-induced loss of dopaminergic neurons in the substantia nigra pars compacta. Combining MSX-3 and MPEP further improved the neuroprotective effect of either antagonists. At the behavioral level, ANR 94 and MSX-3 given alone significantly potentiated l-DOPA-induced turning behavior. Combination of either A2AR antagonists with MPEP synergistically increased L-DOPA-induced turning. This effect was dose-dependent and required subthreshold drug concentration, which per se had no motor stimulating effect. Our findings suggest that co-treatment with A2AR and mGluR5 antagonists provides better therapeutic benefits than those produced by either drug alone. Our study sheds some light on the efficacy and advantages of combined non-dopaminergic PD treatment using low drug concentration and establishes the basis for in-depth studies to identify optimal doses at which these drugs reach highest efficacy.",
keywords = "6-OHDA, adenosine A<inf>2A</inf> receptor, antagonist, metabotropic glutamate receptor, neurodegeneration, neuroprotection",
author = "Fuzzati-Armentero, {Marie Therese} and Silvia Cerri and Giovanna Levandis and Giulia Ambrosi and Elena Montepeloso and Gianfilippo Antoninetti and Fabio Blandini and Younis Baqi and M{\"u}ller, {Christa E.} and Rosaria Volpini and Giulia Costa and Nicola Simola and Annalisa Pinna",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/jnc.13162",
language = "English",
volume = "134",
pages = "740--747",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Dual target strategy

T2 - Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease

AU - Fuzzati-Armentero, Marie Therese

AU - Cerri, Silvia

AU - Levandis, Giovanna

AU - Ambrosi, Giulia

AU - Montepeloso, Elena

AU - Antoninetti, Gianfilippo

AU - Blandini, Fabio

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Volpini, Rosaria

AU - Costa, Giulia

AU - Simola, Nicola

AU - Pinna, Annalisa

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2AR) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2AR antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94). Chronic treatment with MPEP or MSX-3 alone, but not with ANR 94, reduced the toxin-induced loss of dopaminergic neurons in the substantia nigra pars compacta. Combining MSX-3 and MPEP further improved the neuroprotective effect of either antagonists. At the behavioral level, ANR 94 and MSX-3 given alone significantly potentiated l-DOPA-induced turning behavior. Combination of either A2AR antagonists with MPEP synergistically increased L-DOPA-induced turning. This effect was dose-dependent and required subthreshold drug concentration, which per se had no motor stimulating effect. Our findings suggest that co-treatment with A2AR and mGluR5 antagonists provides better therapeutic benefits than those produced by either drug alone. Our study sheds some light on the efficacy and advantages of combined non-dopaminergic PD treatment using low drug concentration and establishes the basis for in-depth studies to identify optimal doses at which these drugs reach highest efficacy.

AB - The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2AR) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2AR antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94). Chronic treatment with MPEP or MSX-3 alone, but not with ANR 94, reduced the toxin-induced loss of dopaminergic neurons in the substantia nigra pars compacta. Combining MSX-3 and MPEP further improved the neuroprotective effect of either antagonists. At the behavioral level, ANR 94 and MSX-3 given alone significantly potentiated l-DOPA-induced turning behavior. Combination of either A2AR antagonists with MPEP synergistically increased L-DOPA-induced turning. This effect was dose-dependent and required subthreshold drug concentration, which per se had no motor stimulating effect. Our findings suggest that co-treatment with A2AR and mGluR5 antagonists provides better therapeutic benefits than those produced by either drug alone. Our study sheds some light on the efficacy and advantages of combined non-dopaminergic PD treatment using low drug concentration and establishes the basis for in-depth studies to identify optimal doses at which these drugs reach highest efficacy.

KW - 6-OHDA

KW - adenosine A<inf>2A</inf> receptor

KW - antagonist

KW - metabotropic glutamate receptor

KW - neurodegeneration

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84937813089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937813089&partnerID=8YFLogxK

U2 - 10.1111/jnc.13162

DO - 10.1111/jnc.13162

M3 - Article

VL - 134

SP - 740

EP - 747

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -